Ligand Enters into OmniAb Platform License Agreement with Ferring Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with its worldwide OmniAb Platform License Agreement with Ferring Pharmaceuticals. Ferrig will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ for human antibody discovery. Under the agreement, Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Read the press release.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.